Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook

No abstract is available for this paper.

• Publication year

  2013

• Venue

  BioDrugs

• Publication date

  2013-05-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s40259-013-0016-7PMID 23696252
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.

  2013cited by this paper
• Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin

  2013cited by this paper
• Novel biological treatments for systemic lupus erythematosus: current and future modalities.

  2012cited by this paper
• OncoImmunology: a new journal at the frontier between oncology and immunology

  2012cited by this paper
• Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

  2012cited by this paper
• Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

  2012cited by this paper
• Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy

  2012cited by this paper
• Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22

  2012cited by this paper
• CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy.

  2012cited by this paper
• Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma

  2012cited by this paper
• Antibody–drug conjugates – a perfect synergy

  2012cited by this paper
• Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

  2012cited by this paper
• Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial

  2012cited by this paper
• Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies

  2011cited by this paper
• Investigational antibody-drug conjugates for hematological malignancies

  2011cited by this paper
• Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.

  2011cited by this paper
• Regulation of B Cell Functions by the Sialic Acid-Binding Receptors Siglec-G and CD22

  2011cited by this paper
• A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

  2011cited by this paper
• Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2

  2011cited by this paper
• Immunotoxins with decreased immunogenicity and improved activity

  2011cited by this paper
• Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.

  2011cited by this paper
• Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin

  2011cited by this paper
• CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells

  2011cited by this paper
• Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP

  2011cited by this paper
• Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non–Hodgkin's Lymphoma Xenograft Mouse Model

  2010cited by this paper
• Oversight of fast-track drug approval by FDA stuck in low gear, critics say.

  2010cited by this paper
• In vivo targeting of B-cell lymphoma with glycan ligands of CD22.

  2010cited by this paper
• Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.

  2010cited by this paper
• High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.

  2010cited by this paper
• FDA increases focus on postmarketing studies.

  2010cited by this paper
• Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma

  2010cited by this paper
• Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

  2010cited by this paper
• Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era.

  2010cited by this paper
• Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts

  2009cited by this paper
• Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)

  2009cited by this paper
• Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia.

  2009cited by this paper
• Developmental Acquisition of the Lyn-CD22-SHP-1 Inhibitory Pathway Promotes B Cell Tolerance1

  2009cited by this paper
• Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B‐cell lymphoma

  2009cited by this paper
• Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab)

  2008cited by this paper
• CD22: an inhibitory enigma

  2008cited by this paper
• Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].

  2008cited by this paper
• Durable complete responses from therapy with combined epratuzumab and rituximab

  2008cited by this paper
• Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.

  2008cited by this paper
• Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.

  2007cited by this paper
• Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.

  2007cited by this paper
• Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.

  2007cited by this paper
• Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia

  2007cited by this paper
• Distinct Endocytic Mechanisms of CD22 (Siglec-2) and Siglec-F Reflect Roles in Cell Signaling and Innate Immunity

  2007cited by this paper
• Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.

  2006cited by this paper
• B Cell Antigen Receptor and CD40 Differentially Regulate CD22 Tyrosine Phosphorylation1

  2006cited by this paper
• Epratuzumab in the therapy of oncological and immunological diseases

  2006cited by this paper
• High-Affinity Ligand Probes of CD22 Overcome the Threshold Set by cis Ligands to Allow for Binding, Endocytosis, and Killing of B Cells1

  2006cited by this paper
• Lyn tyrosine kinase: accentuating the positive and the negative.

  2005cited by this paper
• Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

  2005cited by this paper
• Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab

  2005cited by this paper
• Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma

  2004cited by this paper
• Neuronal expression of CD22: Novel mechanism for inhibiting microglial proinflammatory cytokine production

  2004cited by this paper
• Follicular lymphoma international prognostic index.

  2004cited by this paper
• CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms

  2004cited by this paper
• 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

  2003cited by this paper
• Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

  2003cited by this paper
• Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.

  2003cited by this paper
• B cell defects in SLP65/BLNK‐deficient mice can be partially corrected by the absence of CD22, an inhibitory coreceptor for BCR signaling

  2003cited by this paper
• Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.

  2003cited by this paper
• Difference in CD22 molecules in human B cells and basophils.

  2002cited by this paper
• Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).

  2002cited by this paper
• Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).

  2002cited by this paper
• Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.

  2002cited by this paper
• Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

  2002cited by this paper
• CD22 Regulates B Cell Receptor-mediated Signals via Two Domains That Independently Recruit Grb2 and SHP-1*

  2001cited by this paper
• Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

  2001cited by this paper
• CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.

  1997cited by this paper
• Generation of a high‐producing clone of a humanized anti‐B‐cell lymphoma monoclonal antibody (hLL2)

  1997cited by this paper
• Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

  1996cited by this paper
• Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies.

  1996cited by this paper
• Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand

  1995cited by this paper
• Chimerization of LL2, a Rapidly Internalizing Antibody Specific for B Cell Lymphoma

  1994cited by this paper
• Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.

  1993cited by this paper
• 90 Y-DOTA-hLL2: An Agent for Radioimmunotherapy of Non-Hodgkin’s Lymphoma R adioimmunotherapy for hematologic malignancies

  year unknowncited by this paper

• An ultrasensitive and modular platform to detect Siglec ligands and control immune cell function

  2025cites this paper
• Expression and functional characterization of an anti-CD22 scFv targeting B-cell malignancies

  2025cites this paper
• An ultrasensitive and modular platform to detect Siglec ligands and control immune cell function

  2025cites this paper
• Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma

  2024cites this paper
• From mechanism to therapy: the journey of CD24 in cancer

  2024cites this paper
• Unveiling the hub genes in the SIGLECs family in colon adenocarcinoma with machine learning

  2024cites this paper
• Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies

  2023cites this paper
• An antibody fragment-decorated liposomal conjugate targets Philadelphia-like acute lymphoblastic leukemia.

  2023cites this paper
• Gradation control in the hydrodynamic diameters of mixed glycan-aglycan glycovesicles

  2023cites this paper
• [211At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies

  2023cites this paper
• Multi-omics analysis of Siglec family genes in cutaneous melanoma

  2023cites this paper
• Principle and Progress of Treating Lymphoma with CD22 as Immunotherapy Target

  2023cites this paper
• Multi-omics landscape and clinical signi cance of Siglec family genes: Implications for risk strati cation and front line therapies in cutaneous melanoma

  2022cites this paper
• Conformationally Constrained Sialyl Analogues as New Potential Binders of h‐CD22

  2022cites this paper
• Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences

  2022cites this paper
• Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?

  2022cites this paper
• CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models

  2022cites this paper
• The global landscape of approved antibody therapies

  2022cites this paper
• A Novel Anti-CD22 scFv.Bim Fusion Protein Effectively Induces Apoptosis in Malignant B cells and Promotes Cytotoxicity

  2022influential citation
• Radiotheranostic Agents in Hematological Malignancies

  2022cites this paper
• Polysialylated Nanoinducer for Precisely Enhancing Apoptosis and Anti-tumor Immune Response in B-cell Lymphoma.

  2022cites this paper
• Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22

  2022cites this paper
• Integrative Analysis of the Expression of SIGLEC Family Members in Lung Adenocarcinoma via Data Mining

  2021cites this paper
• OTT_A_312904 4023..4037

  2021cites this paper
• Radiolabeled Antibodies for Cancer Radioimmunotherapy

  2021cites this paper
• Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments

  2021cites this paper
• Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy

  2021cites this paper
• Advances in immunotherapeutic targets for childhood cancers: a focus on glypican-2 and B7-H3.

  2021cites this paper
• From barriers to bridges; glycans in nonparenteral nanomedicines

  2021cites this paper
• Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress

  2020cites this paper
• Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy

  2020cites this paper
• Surface Ligand Density Switches Glycovesicles between Monomeric and Multimeric Lectin Recognition

  2020cites this paper
• Identification of a moderate affinity CD22 binding peptide and in vitro optimization of peptide-targeted nanoparticles for selective uptake by CD22+ B-cell malignancies.

  2020cites this paper
• Advances in targeted therapy for malignant lymphoma

  2020cites this paper
• Functional Study of a Camelid Single Domain Anti-CD22 Antibody

  2019cites this paper
• Characterisation of the Dynamic Interactions between Complex N‐Glycans and Human CD22

  2019cites this paper
• Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia

  2019cites this paper
• A sulfonamide sialoside analog for targeting Siglec-8 and -F on im-mune cells.

  2019cites this paper
• Differential Diagnosis in Hypogammaglobulinemia

  2018cites this paper
• Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.

  2018cites this paper
• Advances in Treatments and Animal Models of Peanut Allergy

  2018cites this paper
• CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity

  2018cites this paper
• Cell-based glycan arrays for probing glycan–glycan binding protein interactions

  2018cites this paper
• Protein corona–mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses

  2018cites this paper
• Sialic Acid and Its Role in Immune Regulation

  2018cites this paper
• Development and characterization of a camelid single‐domain antibody directed to human CD22 biomarker

  2018cites this paper
• New Human CD22/Siglec‐2 Ligands with a Triazole Glycoside

  2017cites this paper
• Molecular basis of human CD22 function and therapeutic targeting

  2017cites this paper
• New Therapeutic Strategies in Acute Lymphocytic Leukemia

  2017cites this paper
• Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells

  2017cites this paper
• Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry

  2017cites this paper
• A novel anti-CD22 scFv–apoptin fusion protein induces apoptosis in malignant B-cells

  2017influential citation
• Characterization of the anti‐CD22 targeted therapy, moxetumomab pasudotox, for B‐cell precursor acute lymphoblastic leukemia

  2017cites this paper
• Polymerizable Peptide Monomers for the Targeted and Intracellular Delivery of Cancer Therapeutics

  2016cites this paper
• Antibody Drug Conjugates for Cancer Therapy

  2016cites this paper
• Emerging immunotherapy in pediatric lymphoma.

  2016cites this paper
• High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab

  2016cites this paper
• A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells

  2016influential citation
• Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.

  2016cites this paper
• Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma

  2016cites this paper
• Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.

  2016cites this paper
• Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.

  2016cites this paper
• Role of biomarkers for early detection of intra-abdominal sepsis: a clinician's perspective.

  2015cites this paper
• Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients

  2015cites this paper
• A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells

  2015cites this paper
• Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms

  2015cites this paper
• Novel therapeutic options for relapsed hairy cell leukemia

  2015cites this paper
• Targeted Therapies in Adult B-Cell Malignancies

  2015cites this paper
• Emerging immunological drugs for chronic lymphocytic leukemia

  2015cites this paper
• Ribosome-inactivating proteins and their immunotoxins for cancer therapy: insights into the mechanism of cell death

  2015cites this paper
• Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.

  2015cites this paper
• Childhood relapsed acute lymphoblastic leukemia: Biology and recent treatment progress

  2015cites this paper
• Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.

  2014cites this paper
• istone deacetylase inhibition enhances the lymphomacidal activity f the anti-CD 22 monoclonal antibody HB 22 . 7

  2014cites this paper
• Discovery of multifold modified sialosides as human CD22/Siglec-2 ligands with nanomolar activity on B-cells.

  2014cites this paper
• Targeted therapy with MXD3 siRNA, anti‐CD22 antibody and nanoparticles for precursor B‐cell acute lymphoblastic leukaemia

  2014cites this paper
• Disubstituted Sialic Acid Ligands Targeting Siglecs CD33 and CD22 Associated with Myeloid Leukaemias and B Cell Lymphomas.

  2014cites this paper
• Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute

  2014cites this paper
• Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute

  2014cites this paper
• Siglec-mediated regulation of immune cell function in disease

  2014cites this paper
• How immunoglobulin G antibodies kill target cells: revisiting an old paradigm.

  2014cites this paper